free性video西欧极品,伊人依成久久人综合网,中文字幕人妻一区二区三区熟女,男女高潮激烈无遮挡免费观软件 ,成人3d动漫一区二区三区

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA grants fast-track designation for Karyopharm's selinexor in penta-refractory multiple myeloma

firstwordpharmaApril 11, 2018

Tag: FDA , Karyopharm's selinexor

Karyopharm Therapeutics announced Tuesday that the FDA granted fast-track status to selinexor, the company's oral selective inhibitor of nuclear export (SINE) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy. According to Karyopharm, the FDA's statement, which is consistent with the design of the company's Phase IIb STORM study, noted that the three prior lines of therapy include regimens comprised of an alkylating agent, a glucocorticoid, Velcade (bortezomib), Kyprolis (carfilzomib), Revlimid (lenalidomide), Pomalyst (pomalidomide) and Darzalex (daratumumab). 

Register as Visitor to CPhI China 2018!

Previous:CROMSOURCE Offers Clients One Trial One Price? Guarantee

Next:Oliver Healthcare Packaging Expands Global Manufacturing Footprint to Strengthen Local Customer Support and Service in Asia Market

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service